This site is intended for Healthcare professionals only.

Orchid Pharma gets EIR from USFDA for its Chennai facility

Orchid Pharma gets EIR from USFDA for its Chennai facility

New Delhi: Drug firm Orchid Pharma said it has received Establishment Inspection Report (EIR) from the US health regulator for its Chennai facility.

The company has received the EIR from the United States Food and Drug Administration (USFDA) on successful inspection closure for the post-marketing adverse drug experience reporting inspection (PADE) conducted at Nungambakkam, Chennai facility, Orchid Pharma said in a BSE filing.

“The facility was inspected by USFDA in the month of June 2017, it added.

As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.

Source: PTI
0 comment(s) on Orchid Pharma gets EIR from USFDA for its Chennai facility

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted